DK3774859T3 - Sammensætninger af rekombinante fusionsproteiner af human neuregulin-1 (nrg-1) og fremgangsmåder til anvendelse deraf - Google Patents

Sammensætninger af rekombinante fusionsproteiner af human neuregulin-1 (nrg-1) og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK3774859T3
DK3774859T3 DK19723548.4T DK19723548T DK3774859T3 DK 3774859 T3 DK3774859 T3 DK 3774859T3 DK 19723548 T DK19723548 T DK 19723548T DK 3774859 T3 DK3774859 T3 DK 3774859T3
Authority
DK
Denmark
Prior art keywords
nrg
compositions
methods
fusion proteins
recombinant human
Prior art date
Application number
DK19723548.4T
Other languages
English (en)
Inventor
John Li
Shengwei Li
Dixiang Luo
Yiran Wu
Ming Zhou
Xiaolei Zhuang
Liang Hua
Pengyi Luo
Yang Wang
Original Assignee
Salubris Biotherapeutics Inc
Salubris Chengdu Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salubris Biotherapeutics Inc, Salubris Chengdu Biotech Co Ltd filed Critical Salubris Biotherapeutics Inc
Application granted granted Critical
Publication of DK3774859T3 publication Critical patent/DK3774859T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
DK19723548.4T 2018-04-11 2019-04-11 Sammensætninger af rekombinante fusionsproteiner af human neuregulin-1 (nrg-1) og fremgangsmåder til anvendelse deraf DK3774859T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862656246P 2018-04-11 2018-04-11
PCT/US2019/026889 WO2019200033A1 (en) 2018-04-11 2019-04-11 Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
DK3774859T3 true DK3774859T3 (da) 2024-05-27

Family

ID=66484143

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19723548.4T DK3774859T3 (da) 2018-04-11 2019-04-11 Sammensætninger af rekombinante fusionsproteiner af human neuregulin-1 (nrg-1) og fremgangsmåder til anvendelse deraf

Country Status (21)

Country Link
US (3) US11046741B2 (da)
EP (2) EP4361177A2 (da)
JP (2) JP2021535727A (da)
KR (1) KR20210022542A (da)
CN (1) CN113166218A (da)
AU (2) AU2019252262B2 (da)
BR (1) BR112020020646A2 (da)
CA (1) CA3096420A1 (da)
CL (1) CL2020002621A1 (da)
CO (1) CO2020012621A2 (da)
DK (1) DK3774859T3 (da)
EA (1) EA202092458A1 (da)
FI (1) FI3774859T3 (da)
IL (1) IL277790A (da)
MX (1) MX2020010740A (da)
PE (1) PE20210111A1 (da)
PH (1) PH12020551648A1 (da)
PT (1) PT3774859T (da)
SG (1) SG11202009831UA (da)
TW (1) TWI834654B (da)
WO (1) WO2019200033A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020646A2 (pt) 2018-04-11 2021-02-23 Salubris Biotherapeutics, Inc. composições de proteína de fusão recombinante de neuregulina-1 (nrg-1) humana e métodos de uso destas
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
AU2020348436A1 (en) * 2019-09-16 2022-04-07 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant human neuregulin derivatives and use thereof
WO2023178086A1 (en) * 2022-03-15 2023-09-21 Salubris Biotherapeutics, Inc. Methods of treating fibrosis and arrhythmia with a neuregulin-1 fusion protein

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
WO2006017184A2 (en) * 2004-07-09 2006-02-16 Wayne State University HYBRID PROTEINS WITH ErbB4 EXTRACELLULAR DOMAIN AND NEUREGULIN HEPARIN-BINDING DOMAIN FOR TARGETING
US8142781B2 (en) 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
US20070213264A1 (en) * 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
WO2009052184A2 (en) 2007-10-16 2009-04-23 Receptor Biologix, Inc. Compositions comprising optimized her1 and her3 multimers and methods of use thereof
WO2009114110A1 (en) * 2008-03-08 2009-09-17 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
WO2010006059A1 (en) * 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 binding proteins and uses thereof
JP5743898B2 (ja) 2008-11-28 2015-07-01 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
CA2775573A1 (en) * 2009-10-09 2011-04-14 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her 3 antibodies
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2011119836A1 (en) * 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
WO2015067986A1 (en) * 2013-11-07 2015-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Neuregulin allosteric anti-her3 antibody
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
ES2859648T3 (es) * 2014-04-10 2021-10-04 Daiichi Sankyo Co Ltd Conjugado anticuerpo-fármaco anti-HER3
CA2959716A1 (en) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
AU2017214692B2 (en) 2016-02-06 2021-11-04 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
US11008402B2 (en) 2016-09-15 2021-05-18 Universitat Stuttgart Antigen binding protein against HER3
BR112020020646A2 (pt) 2018-04-11 2021-02-23 Salubris Biotherapeutics, Inc. composições de proteína de fusão recombinante de neuregulina-1 (nrg-1) humana e métodos de uso destas

Also Published As

Publication number Publication date
EP3774859B1 (en) 2024-03-13
WO2019200033A1 (en) 2019-10-17
US11046741B2 (en) 2021-06-29
SG11202009831UA (en) 2020-11-27
US20230322877A1 (en) 2023-10-12
CA3096420A1 (en) 2019-10-17
AU2023285793A1 (en) 2024-01-18
AU2019252262A1 (en) 2020-10-22
US20210347841A1 (en) 2021-11-11
MX2020010740A (es) 2021-01-20
EP3774859A1 (en) 2021-02-17
EA202092458A1 (ru) 2021-02-08
PH12020551648A1 (en) 2021-07-26
CL2020002621A1 (es) 2021-06-11
KR20210022542A (ko) 2021-03-03
PT3774859T (pt) 2024-05-27
JP2021535727A (ja) 2021-12-23
FI3774859T3 (fi) 2024-05-24
EP4361177A2 (en) 2024-05-01
CN113166218A (zh) 2021-07-23
CO2020012621A2 (es) 2020-12-21
US20200010522A1 (en) 2020-01-09
BR112020020646A2 (pt) 2021-02-23
IL277790A (en) 2020-11-30
AU2019252262B2 (en) 2023-10-05
US11718652B2 (en) 2023-08-08
PE20210111A1 (es) 2021-01-19
TWI834654B (zh) 2024-03-11
TW201945389A (zh) 2019-12-01
JP2023134436A (ja) 2023-09-27

Similar Documents

Publication Publication Date Title
DK3774859T3 (da) Sammensætninger af rekombinante fusionsproteiner af human neuregulin-1 (nrg-1) og fremgangsmåder til anvendelse deraf
DK4011908T3 (da) Ultralangtidsvirkende insulin-FC-fusionsproteiner og fremgangsmåder til anvendelse deraf
DK3794024T3 (da) Aktiverbare interleukin-2 polypeptider og fremgangsmåder til anvendelse heraf
IL279510A (en) Progranulin-FC polypeptide fusion proteins and their uses
DK3298033T4 (da) Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner
DK3565579T3 (da) Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
DK3445787T3 (da) Sammensætninger og fremgangsmåder til omprogrammering af t-cellereceptorer under anvendelse af fusionsproteiner
DK4073098T3 (da) Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse
IL287273A (en) Recombinant polyclonal proteins and methods of using them
DK3368554T3 (da) Langtidsvirkende fgf21-fusionsproteiner og farmaceutisk sammensætning omfattende samme
DK3565828T3 (da) Sirp1 alpha-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
IL281962A (en) Proteins from IL-12 heterodimers-FC
IL280102A (en) Fusion protein containing PD1-4-1BBL and methods of using it
DK3615066T3 (da) Formuleringer af humane anti-rankl-antistoffer og fremgangsmåder til anvendelse deraf
DK3628049T3 (da) Tgf-beta-receptortype-ii-fusionsproteiner og anvendelser deraf
DK3399985T3 (da) Sammensætninger og biblioteker, der omfatter rekombinante T-cellereceptorer, og fremgangsmåder til anvendelse af rekombinante T-cellereceptorer
DK3972987T3 (da) Antigenspecifik immunterapi til COVID-19-fusionsproteiner og fremgangsmåder til anvendelse deraf
DK3618928T3 (da) Anti-Sortilin-antistoffer og fremgangsmåder til anvendelse deraf
IL275779A (en) Recombinant human sialidases, sialidase-related proteins and methods of using them
DK3743088T3 (da) IL-22 Fc-sammensætninger og fremgangsmåder til anvendelse
DK3325011T3 (da) Fusionsproteiner af humane proteinfragmenter til fremstilling af ordnede multimeriserede immunoglobulin Fc-sammensætninger med forstærket komplementbinding
SG11202013167UA (en) SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
DK3536776T3 (da) Hidtil ukendte vertebratceller og fremgangsmåder til rekombinant ekspression af et polypeptid af interesse
MA53020A (fr) Protéine de fusion du fviii améliorée et utilisation associée
DK3660545T3 (da) Silikonehydrogelsammensætning, silikonehydrogellinse og fremgangsmåde til fremstilling af silikonehydrogellinse